Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma

Elisabet Aliagas(Institut d'Investigació Biomédica de Bellvitge), Ernest Nadal(Institut d'Investigació Biomédica de Bellvitge)

bioRxiv (Cold Spring Harbor Laboratory)

February 8, 2021

10.1101/2021.02.08.430196

Cited by 1

Related Papers

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target

|Molecular Cancer|2018|306